Search 7,500+ licensed pharmacies to find the best value, closest location, and fastest turnaround for
.
Omeprazole irreversibly inhibits H+/K+-ATPase (the proton pump) on the apical surface of gastric parietal cells, dramatically reducing acid secretion. It requires activation in the acidic environment of the secretory canaliculi.
Commercial omeprazole capsules contain multiple dyes and fillers problematic for MCAS and chemically sensitive patients. Compounding provides dye-free, lactose-free, gluten-free formulations and liquid suspensions for pediatric use or patients with dysphagia.
Compare up to 7,500 pharmacies across the USA.
Omeprazole is one of the most commonly prescribed medications worldwide for acid-related conditions including GERD, H. pylori eradication, and Zollinger-Ellison syndrome. While OTC versions are available, compounded formulations offer critical advantages for specific patient populations.
MCAS patients often react to commercial omeprazole dyes and excipients. Compounded dye-free, preservative-free omeprazole capsules allow these patients to benefit from PPI therapy without triggering reactions. Pediatric liquid suspensions are also critical since commercial formulations don't come in reliable liquid form.
Proton Pump Inhibition
Omeprazole is a substituted benzimidazole prodrug that is activated by the acidic environment of the gastric parietal cell secretory canaliculus. The activated sulfenamide form covalently and irreversibly binds to cysteine residues on the H+/K+-ATPase (proton pump), blocking acid secretion.
Acid Suppression Profile
Because omeprazole irreversibly inhibits proton pumps, acid suppression lasts 18–24 hours despite a plasma half-life of only 1–2 hours. New pump synthesis takes 18+ hours, explaining the once-daily dosing schedule. Maximal suppression is reached after 3–4 days of daily dosing.
GERD (gastroesophageal reflux disease), peptic ulcer disease, H. pylori eradication (triple therapy), MCAS with GI manifestations, Zollinger-Ellison syndrome, eosinophilic esophagitis, pediatric acid reflux, Barrett's esophagus management
H. pylori eradication (triple therapy component), Barrett's esophagus surveillance management, prevention of NSAID-induced gastric ulcers, systemic mastocytosis (acid hypersecretion), eosinophilic esophagitis (in combination protocols)
Adult GERD: 20–40mg once daily 30–60 minutes before breakfast
H. pylori triple therapy: 20mg twice daily
Pediatric (≥1 year): Weight-based dosing, typically 0.7–1.4mg/kg/day
Note: Take 30–60 minutes before first meal for maximum efficacy
No titration required for standard use. Take 30–60 minutes before the first meal of the day. For patients who need BID dosing (H. pylori eradication, severe GERD), take one dose before breakfast and one before dinner. When discontinuing after long-term use, taper over 2–4 weeks to minimize rebound acid hypersecretion.
Dye-free/Preservative-free Capsules — 20mg or 40mg; no FD&C dyes, no lactose, no gelatin — essential for MCAS patients who react to commercial excipients
Oral Liquid Suspension — typically 2mg/mL or 4mg/mL; used for pediatric patients, NG/G-tube administration, and patients with dysphagia
Custom Strength Capsules — doses outside commercial 20mg/40mg (e.g., 10mg for pediatric or 60mg+ for Zollinger-Ellison) available through compounding
Generally well tolerated short-term. Long-term use risks include C. difficile infection, hypomagnesemia, vitamin B12 deficiency, bone density reduction, and rebound acid hypersecretion on discontinuation. Taper when stopping after prolonged use. Reassess ongoing need periodically.
Submit a quote request to find the lowest price. Quotes delivered to your inbox.
Find Lowest Price.png){kind=spacer}
